Late-Onset Adrenal Hyperplasia in North Indian Hirsute Women

Mithal, Ambrish; Ammini, AC; Godbole, Madan M.; Khurana, ML; Raj, D Henith; Karmarkar, M. G.; Ahuja, Maninder

doi:10.1159/000181016

Cited by 11 publications

(3 citation statements)

References 21 publications

(36 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…PKOS, üreme çağındaki kadınları etkileyen en sık endokrin anomalidir [19]. Mithal ve arkadaşlarının yapmış olduğu bir çalışmada hirsutizmi olan 60 hastanın %75'inde PKOS saptamışlardır [20]. Zargar ve arkadaşları tarafından Hindistanlı 150 hasta üzerinde yapılmış olan bir başka çalışmada ise PKOS insidansı %37,3 olarak saptanmıştır [21].…”

Section: Discussionunclassified

Diagnostic evaluation of patients presenting with hirsutism

Tekiş

Dokuyucu²,

Üstün³

et al. 2014

J Clin Exp Invest

View full text Add to dashboard Cite

Objective: Hirsutism, similar to men, is the presence of terminal hairs in androgen-to sensitive areas in women. The present report aimed to study etiology and determine the prevalence of the diseases that causes hirsutism in these patients. Methods:In this study, total number of 40 patients who admitted because of hirsutism to Department of Endocrinology and Metabolism clinic was enrolled. Demographic, clinical and laboratory parameters of the patients were evaluated.Results: Result of the study showed that polycystic ovary syndrome is the most common cause of hirsutism. The second most common cause was found as idiopathic hirsutism. Conclusion:By the present study, etiologic factors of hirsutism were examined firstly in our region in which Ethnic and cultural diversity is concentrated. In rare cases like Cushing's syndrome, hyperprolactinemia, non-classic adrenal hyperplasia, androgen-secreting tumors should be considered in the differential diagnosis of hirsutism.

show abstract

Section: Discussionunclassified

Diagnostic evaluation of patients presenting with hirsutism

Tekiş

Dokuyucu²,

Üstün³

et al. 2014

J Clin Exp Invest

View full text Add to dashboard Cite

show abstract

“…16 The disorder affects between 1 and 10% of hyperandrogenic women, depending on the ethnicity of the population studied. 2,14,[17][18][19][20][21][22][23][24][25] In the United States, we and others have observed an NCAH prevalence of 1 to 2% among populations of white and Hispanic hyperandrogenic patients. 2,14,17,18 In contrast, studies in France, Italy, and Canada yield frequencies of 4 to 6%, [19][20][21] and other studies originating in Israel, India, and Jordan demonstrate prevalences of 6 to 10%.…”

Section: Prevalencementioning

confidence: 99%

“…2,14,17,18 In contrast, studies in France, Italy, and Canada yield frequencies of 4 to 6%, [19][20][21] and other studies originating in Israel, India, and Jordan demonstrate prevalences of 6 to 10%. [22][23][24][25] We can conclude that there are important differences in the prevalence of PCOS and NCAH, as the frequency of PCOS is approximately 40 to 50 times higher than that of NCAH in the general population of reproductive-aged women or among hyperandrogenic patients.…”

Section: Prevalencementioning

confidence: 99%

21-Hydroxylase-Deficient Nonclassic Adrenal Hyperplasia: The Great Pretender

Morán

Azziz²

2003

Semin Reprod Med

View full text Add to dashboard Cite

Polycystic ovary syndrome (PCOS) affects about 4 to 6% of women of reproductive age and accounts for at least 75% of hyperandrogenic patients. PCOS is diagnosed by the presence of oligo-ovulation and hyperandrogenism after the exclusion of related disorders, such as 21-hydroxylase-deficient nonclassic adrenal hyperplasia (NCAH). In turn, NCAH is a homozygous recessive disorder, diagnosed by a corticotropin-stimulated 17-hydroxyprogesterone (17-HP) level greater than10 ng/mL (30.3 nmol/L) and confirmed by genotyping of the CYP21 gene. The prevalence of NCAH is approximately 50 times less than that of PCOS, affecting between 1 and 10% of hyperandrogenic women, depending on ethnicity. However, it is generally difficult to distinguish NCAH from PCOS solely on clinical grounds, as both demonstrate varying degrees of hyperandrogenism and ovulatory dysfunction. Most PCOS patients have insulin resistance, in contrast to those with NCAH. Likewise, polycystic ovaries are observed in up to 40% of NCAH patients. Both disorders have a strong familial component. The only method that allows the separation of NCAH from PCOS patients is the measurement of 17-HP levels. In conclusion, PCOS and NCAH have differences in prevalence and pathophysiology. However, because the disorders have significant clinical and hormonal similarities, the measurement of 17-HP, preferably basally as a screening method, should be incorporated into the evaluation of all hyperandrogenic patients.

show abstract